Prevalence of high blood pressure and hypertension among children and adolescents in Europe: a systematic review and meta-analysis
- PMID: 41161717
- DOI: 10.1136/archdischild-2025-329073
Prevalence of high blood pressure and hypertension among children and adolescents in Europe: a systematic review and meta-analysis
Abstract
Objective: This systematic review and meta-analysis aims to estimate the prevalence of high blood pressure (BP) and hypertension among European children and adolescents (1990-present).
Methods: We included population-based cross-sectional and cohort studies reporting BP in children (≤18 years) from European countries, excluding studies from electronic health records or specialist care referrals. PubMed was searched on 27 January 2025. Risk of bias was assessed with the Hoy et al tool, and data were pooled using random-effects meta-analysis. The main outcomes were pooled prevalence of high BP and hypertension.
Results: We analysed 56 studies (n=179 279, mean age, 12 years) from 18 European countries. The prevalence of high BP was 8% (95% CI 7% to 10%), higher in boys (7%, 95% CI 6% to 9%) than in girls (5%, 95% CI 4% to 7%). Among children with obesity, prevalence was 23% (95% CI 18% to 29%) vs 6% (95% CI 4% to 9%) in children without obesity. Prevalence was highest in 10-13 years old (8% (95% CI 5% to 13%) compared with 6% (95% CI 4% to 8%) and 6% (95% CI 3% to 9%) in 3-9 years old and 14-19 years old, respectively. The prevalence of hypertension was 4% (95% CI 3% to 5%). Risk of bias was judged to be moderate or high for most studies, with variability in BP measurement methods.
Conclusions: The prevalence of high BP and hypertension among European children and adolescents is considerable, particularly among those with obesity, where one-fourth has high BP. It is more common in boys and peaks during puberty. These findings should be interpreted with caution due to methodological limitations of the included studies.
Keywords: Adolescent Health; Child Health; Epidemiology; Hypertension; Obesity.
© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.
Conflict of interest statement
Competing interests: MB has received consultancy fees from Amarin and AstraZeneca, and lecture honouraria from Amarin, AstraZeneca and Medtronic. HR, GS, EW and EL report no conflicts of interest.
LinkOut - more resources
Full Text Sources